A randomized controlled trial of oral versus intravenous iron in chronic kidney disease - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1159/000096174. Epub 2006 Oct 11.
Affiliations
- PMID: 17035697
- DOI: 10.1159/000096174
Randomized Controlled Trial
A randomized controlled trial of oral versus intravenous iron in chronic kidney disease
Rajiv Agarwal et al. Am J Nephrol. 2006.
Abstract
Background: It is unknown whether intravenous iron or oral iron repletion alone can correct anemia associated with chronic kidney disease (CKD). We conducted a randomized multicenter controlled trial in adult anemic, iron-deficient non-dialysis CKD (ND-CKD) patients (>or=stage 3) not receiving erythropoiesis-stimulating agents (ESAs).
Methods: The participants were randomized to receive either a sodium ferric gluconate complex (intravenous iron) 250 mg i.v. weekly x 4 or ferrous sulfate (oral iron) 325 mg t.i.d. x 42 days. Hemoglobin (Hgb), ferritin and transferrin saturation (TSAT) were measured serially, and the Kidney Disease Quality of Life (KDQoL) questionnaire was administered on days 1 and 43. The primary outcome variable was change from baseline (CFB) to endpoint in Hgb values.
Results: Seventy-five patients were analyzed (intravenous iron n = 36, oral iron n = 39). CFB in Hgb was similar in the two groups (intravenous iron 0.4 g/dl vs. oral iron 0.2 g/dl, p = n.s.). However, the increase in Hgb was only significant with intravenous iron (p < 0.01). In comparison to oral iron, intravenous iron achieved greater improvements in ferritin (232.0 +/- 160.8 vs. 55.9 +/- 236.2 ng/ml, p < 0.001) and TSAT (8.3 +/- 7.5 vs. 2.9 +/- 8.8%, p = 0.007). Intravenous iron caused greater improvements in KDQoL scores than oral iron (p < 0.05). The most common side effect reported with intravenous iron was hypotension, while constipation was more common with oral iron.
Conclusions: Oral and intravenous iron similarly increase Hgb in anemic iron-depleted ND-CKD patients not receiving ESAs. Although in comparison to oral iron, intravenous iron may result in a more rapid repletion of iron stores and greater improvement in quality of life, it exposes the patients to a greater risk of adverse effects and increases inconvenience and cost.
Copyright (c) 2006 S. Karger AG, Basel.
Similar articles
- Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group. Coyne DW, et al. J Am Soc Nephrol. 2007 Mar;18(3):975-84. doi: 10.1681/ASN.2006091034. Epub 2007 Jan 31. J Am Soc Nephrol. 2007. PMID: 17267740 Clinical Trial. - Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP, Kent AB, Kerr PG, Healy H, Irish AB, Cooper B, Kark A, Roger SD. McMahon LP, et al. Nephrol Dial Transplant. 2010 Mar;25(3):920-6. doi: 10.1093/ndt/gfp584. Epub 2009 Nov 10. Nephrol Dial Transplant. 2010. PMID: 19906658 Clinical Trial. - Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC. Macdougall IC. Curr Med Res Opin. 2010 Feb;26(2):473-82. doi: 10.1185/03007990903512461. Curr Med Res Opin. 2010. PMID: 20014980 Review. - Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC, Geisser P. Macdougall IC, et al. Iran J Kidney Dis. 2013 Jan;7(1):9-22. Iran J Kidney Dis. 2013. PMID: 23314137 Review.
Cited by
- Functional iron deficiency anemia was associated with higher mortality in chronic kidney disease patients: the NHANES III follow-up study.
Gong W, Huang J, Zhu T, Lin S, Hao C, Zhang M. Gong W, et al. Ren Fail. 2023;45(2):2290926. doi: 10.1080/0886022X.2023.2290926. Epub 2023 Dec 7. Ren Fail. 2023. PMID: 38059456 Free PMC article. - Association of oral iron replacement therapy with kidney failure and mortality in CKD patients.
Paul S, Shrestha P, Sumida K, Thomas F, Surbhi S, Naser AM, Streja E, Rhee CM, Kalantar-Zadeh K, Kovesdy CP. Paul S, et al. Clin Kidney J. 2023 Aug 9;16(11):2082-2090. doi: 10.1093/ckj/sfad190. eCollection 2023 Nov. Clin Kidney J. 2023. PMID: 37915900 Free PMC article. - Efficacy of Oral Versus Injectable Iron in Patients With Chronic Kidney Disease: A Two-Year Cross-Sectional Study Conducted at a Rural Teaching Hospital.
Agrawal S, Sonawane S, Kumar S, Acharya S, Gaidhane SA, Wanjari A, Kabra R, Phate N, Ahuja A. Agrawal S, et al. Cureus. 2022 Jul 31;14(7):e27529. doi: 10.7759/cureus.27529. eCollection 2022 Jul. Cureus. 2022. PMID: 36060352 Free PMC article. - Prevalence of Postoperative Micronutrient Deficiencies in Bariatric Surgery Patients Who Use Transdermal Patches for Supplementation: A Pilot Study.
Culpepper T, Lux T, Trivedi S, Neal D, Hazen K, Fleisher M, Samra R, Johnson-Mann C, Friedman J. Culpepper T, et al. Cureus. 2022 Jun 16;14(6):e25989. doi: 10.7759/cureus.25989. eCollection 2022 Jun. Cureus. 2022. PMID: 35859973 Free PMC article. - Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-analysis.
Shah AA, Donovan K, Seeley C, Dickson EA, Palmer AJR, Doree C, Brunskill S, Reid J, Acheson AG, Sugavanam A, Litton E, Stanworth SJ. Shah AA, et al. JAMA Netw Open. 2021 Nov 1;4(11):e2133935. doi: 10.1001/jamanetworkopen.2021.33935. JAMA Netw Open. 2021. PMID: 34767026 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous